Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib

Vismodegib, an inhibitor of the Hedgehog signaling pathway, is an approved drug for monotherapy in locally advanced or metastatic basal cell carcinoma (BCC). Data on combined modality treatment by vismodegib and radiation therapy, however, are rare. In the present study, we examined the radiation se...

Full description

Bibliographic Details
Main Authors: Stephanie Hehlgans, Patrick Booms, Ömer Güllülü, Robert Sader, Claus Rödel, Panagiotis Balermpas, Franz Rödel, Shahram Ghanaati
Format: Article
Language:English
Published: MDPI AG 2018-08-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:http://www.mdpi.com/1422-0067/19/9/2485
id doaj-4f99ca564cf749c592017a6328f4277c
record_format Article
spelling doaj-4f99ca564cf749c592017a6328f4277c2020-11-25T01:02:16ZengMDPI AGInternational Journal of Molecular Sciences1422-00672018-08-01199248510.3390/ijms19092485ijms19092485Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor VismodegibStephanie Hehlgans0Patrick Booms1Ömer Güllülü2Robert Sader3Claus Rödel4Panagiotis Balermpas5Franz Rödel6Shahram Ghanaati7Department of Radiotherapy and Oncology, Medical Center Goethe-University Frankfurt am Main, 60590 Frankfurt am Main, GermanyDepartment for Oral, Cranio-Maxillofacial and Facial Plastic Surgery, Frankfurt Orofacial Regenerative Medicine (FORM), Medical Center Goethe-University Frankfurt am Main, 60590 Frankfurt am Main, GermanyDepartment of Radiotherapy and Oncology, Medical Center Goethe-University Frankfurt am Main, 60590 Frankfurt am Main, GermanyDepartment for Oral, Cranio-Maxillofacial and Facial Plastic Surgery, Frankfurt Orofacial Regenerative Medicine (FORM), Medical Center Goethe-University Frankfurt am Main, 60590 Frankfurt am Main, GermanyDepartment of Radiotherapy and Oncology, Medical Center Goethe-University Frankfurt am Main, 60590 Frankfurt am Main, GermanyDepartment of Radiotherapy and Oncology, Medical Center Goethe-University Frankfurt am Main, 60590 Frankfurt am Main, GermanyDepartment of Radiotherapy and Oncology, Medical Center Goethe-University Frankfurt am Main, 60590 Frankfurt am Main, GermanyDepartment for Oral, Cranio-Maxillofacial and Facial Plastic Surgery, Frankfurt Orofacial Regenerative Medicine (FORM), Medical Center Goethe-University Frankfurt am Main, 60590 Frankfurt am Main, GermanyVismodegib, an inhibitor of the Hedgehog signaling pathway, is an approved drug for monotherapy in locally advanced or metastatic basal cell carcinoma (BCC). Data on combined modality treatment by vismodegib and radiation therapy, however, are rare. In the present study, we examined the radiation sensitizing effects of vismodegib by analyzing viability, cell cycle distribution, cell death, DNA damage repair and clonogenic survival in three-dimensional cultures of a BCC and a head and neck squamous cell carcinoma (HNSCC) cell line. We found that vismodegib decreases expression of the Hedgehog target genes glioma-associated oncogene homologue (GLI1) and the inhibitor of apoptosis protein (IAP) Survivin in a cell line- and irradiation-dependent manner, most pronounced in squamous cell carcinoma (SCC) cells. Furthermore, vismodegib significantly reduced proliferation in both cell lines, while additional irradiation only slightly further impacted on viability. Analyses of cell cycle distribution and cell death induction indicated a G1 arrest in BCC and a G2 arrest in HNSCC cells and an increased fraction of cells in SubG1 phase following combined treatment. Moreover, a significant rise in the number of phosphorylated histone-2AX/p53-binding protein 1 (γH2AX/53BP1) foci in vismodegib- and radiation-treated cells was associated with a significant radiosensitization of both cell lines. In summary, these findings indicate that inhibition of the Hedgehog signaling pathway may increase cellular radiation response in BCC and HNSCC cells.http://www.mdpi.com/1422-0067/19/9/2485basal cell carcinomahead and neck squamous cell carcinomahedgehog signaling pathwayradiotherapy resistancevismodegib (GDC-0449)
collection DOAJ
language English
format Article
sources DOAJ
author Stephanie Hehlgans
Patrick Booms
Ömer Güllülü
Robert Sader
Claus Rödel
Panagiotis Balermpas
Franz Rödel
Shahram Ghanaati
spellingShingle Stephanie Hehlgans
Patrick Booms
Ömer Güllülü
Robert Sader
Claus Rödel
Panagiotis Balermpas
Franz Rödel
Shahram Ghanaati
Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib
International Journal of Molecular Sciences
basal cell carcinoma
head and neck squamous cell carcinoma
hedgehog signaling pathway
radiotherapy resistance
vismodegib (GDC-0449)
author_facet Stephanie Hehlgans
Patrick Booms
Ömer Güllülü
Robert Sader
Claus Rödel
Panagiotis Balermpas
Franz Rödel
Shahram Ghanaati
author_sort Stephanie Hehlgans
title Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib
title_short Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib
title_full Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib
title_fullStr Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib
title_full_unstemmed Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib
title_sort radiation sensitization of basal cell and head and neck squamous cell carcinoma by the hedgehog pathway inhibitor vismodegib
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2018-08-01
description Vismodegib, an inhibitor of the Hedgehog signaling pathway, is an approved drug for monotherapy in locally advanced or metastatic basal cell carcinoma (BCC). Data on combined modality treatment by vismodegib and radiation therapy, however, are rare. In the present study, we examined the radiation sensitizing effects of vismodegib by analyzing viability, cell cycle distribution, cell death, DNA damage repair and clonogenic survival in three-dimensional cultures of a BCC and a head and neck squamous cell carcinoma (HNSCC) cell line. We found that vismodegib decreases expression of the Hedgehog target genes glioma-associated oncogene homologue (GLI1) and the inhibitor of apoptosis protein (IAP) Survivin in a cell line- and irradiation-dependent manner, most pronounced in squamous cell carcinoma (SCC) cells. Furthermore, vismodegib significantly reduced proliferation in both cell lines, while additional irradiation only slightly further impacted on viability. Analyses of cell cycle distribution and cell death induction indicated a G1 arrest in BCC and a G2 arrest in HNSCC cells and an increased fraction of cells in SubG1 phase following combined treatment. Moreover, a significant rise in the number of phosphorylated histone-2AX/p53-binding protein 1 (γH2AX/53BP1) foci in vismodegib- and radiation-treated cells was associated with a significant radiosensitization of both cell lines. In summary, these findings indicate that inhibition of the Hedgehog signaling pathway may increase cellular radiation response in BCC and HNSCC cells.
topic basal cell carcinoma
head and neck squamous cell carcinoma
hedgehog signaling pathway
radiotherapy resistance
vismodegib (GDC-0449)
url http://www.mdpi.com/1422-0067/19/9/2485
work_keys_str_mv AT stephaniehehlgans radiationsensitizationofbasalcellandheadandnecksquamouscellcarcinomabythehedgehogpathwayinhibitorvismodegib
AT patrickbooms radiationsensitizationofbasalcellandheadandnecksquamouscellcarcinomabythehedgehogpathwayinhibitorvismodegib
AT omergullulu radiationsensitizationofbasalcellandheadandnecksquamouscellcarcinomabythehedgehogpathwayinhibitorvismodegib
AT robertsader radiationsensitizationofbasalcellandheadandnecksquamouscellcarcinomabythehedgehogpathwayinhibitorvismodegib
AT clausrodel radiationsensitizationofbasalcellandheadandnecksquamouscellcarcinomabythehedgehogpathwayinhibitorvismodegib
AT panagiotisbalermpas radiationsensitizationofbasalcellandheadandnecksquamouscellcarcinomabythehedgehogpathwayinhibitorvismodegib
AT franzrodel radiationsensitizationofbasalcellandheadandnecksquamouscellcarcinomabythehedgehogpathwayinhibitorvismodegib
AT shahramghanaati radiationsensitizationofbasalcellandheadandnecksquamouscellcarcinomabythehedgehogpathwayinhibitorvismodegib
_version_ 1725205651283509248